# A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

> **NCT01271790** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 245 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** Tegobuvir (GS-9190)
- **DRUG:** GS-9451
- **BIOLOGICAL:** Pegasys®
- **DRUG:** Copegus®
- **DRUG:** GS-9451
- **DRUG:** Tegobuvir placebo
- **BIOLOGICAL:** Pegasys®
- **DRUG:** Copegus®
- **DRUG:** Tegobuvir placebo
- **DRUG:** GS-9451 placebo
- **BIOLOGICAL:** Pegasys®
- **DRUG:** Copegus®

## Key facts

- **NCT ID:** NCT01271790
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-10
- **Primary completion:** 2013-01
- **Final completion:** 2013-09
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01271790

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01271790, "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01271790. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*